No abstract available
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma / blood supply
-
Carcinoma / drug therapy*
-
Carcinoma / metabolism
-
Carcinoma / pathology
-
Drug Delivery Systems / methods*
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
ErbB Receptors / physiology
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genes, ras
-
Humans
-
Lung Neoplasms / blood supply
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology
-
Mutation
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / physiology
-
Neoplastic Stem Cells / drug effects
-
Neovascularization, Pathologic / drug therapy
-
Patient Selection
-
Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors
-
Proto-Oncogene Proteins p21(ras) / physiology
-
Signal Transduction / drug effects
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Neoplasm Proteins
-
EGFR protein, human
-
ErbB Receptors
-
Proto-Oncogene Proteins p21(ras)